Morgan Stanley
CLYM

Morgan Stanley’s Climb Bio CLYM Stock Holding History

Morgan Stanley’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76M Buy
365,088
+130,906
+56% +$1.35M ﹤0.01% 4264
2026
Q1 		$1.6M Buy
234,182
+85,644
+58% +$494K ﹤0.01% 4894
2025
Q4 		$594K Buy
148,538
+62,204
+72% +$149K ﹤0.01% 5419
2025
Q3 		$174K Sell
86,334
-13,125
-13% -$24.4K ﹤0.01% 5941
2025
Q2 		$123K Sell
99,459
-77,520
-44% -$96.5K ﹤0.01% 6055
2025
Q1 		$216K Sell
176,979
-49,871
-22% -$80.9K ﹤0.01% 5700
2024
Q4 		$408K Buy
226,850
+148,669
+190% +$538K ﹤0.01% 5506
2024
Q3 		$398K Buy
78,181
+68,298
+691% +$483K ﹤0.01% 5505
2024
Q2 		$70.3K Buy
9,883
+8,174
+478% +$54.4K ﹤0.01% 6081
2024
Q1 		$4.68K Hold
1,709
– – ﹤0.01% 6907
2023
Q4 		$4.61K Hold
1,709
– – ﹤0.01% 6849
2023
Q3 		$4.5K Hold
1,709
– – ﹤0.01% 6938
2023
Q2 		$4.79K Sell
1,709
-60,607
-97% -$184K ﹤0.01% 6995
2023
Q1 		$181K Buy
62,316
+62,171
+42,877% +$214K ﹤0.01% 5751
2022
Q4 		$532 Sell
145
-4,622
-97% -$13.7K ﹤0.01% 7552
2022
Q3 		$15K Sell
4,767
-1,861
-28% -$5.94K ﹤0.01% 6931
2022
Q2 		$20K Buy
6,628
+946
+17% +$4.48K ﹤0.01% 6994
2022
Q1 		$47K Sell
5,682
-4,440
-44% -$41.4K ﹤0.01% 6740
2021
Q4 		$106K Buy
10,122
+4,009
+66% +$59.8K ﹤0.01% 6408
2021
Q3 		$110K Buy
+6,113
New +$126K ﹤0.01% 6312

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's CLYM Position: Q2 2026 in Review

Morgan Stanley increased its Climb Bio (CLYM) stake by 56% in Q2 2026, buying an estimated $1.35M and bringing the position to 365,088 shares worth $4.76M. The position accounts for ﹤0.01% of the portfolio, ranked #4264.

Morgan Stanley first reported a position in CLYM in Q3 2021 and has held it in 20 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Morgan Stanley held 365,088 shares of Climb Bio worth $4.76M as of Q2 2026.
  • Morgan Stanley bought 130,906 Climb Bio shares in Q2 2026, an estimated $1.35M.
  • Climb Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4264 holding.
  • Morgan Stanley first reported a position in Climb Bio in Q3 2021 and has held it in 20 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.